Q2 2022 Earnings Forecast for Aclaris Therapeutics, Inc. Issued By SVB Leerink (NASDAQ:ACRS)

Aclaris Therapeutics, Inc. (NASDAQ:ACRSGet Rating) – Investment analysts at SVB Leerink upped their Q2 2022 earnings per share (EPS) estimates for Aclaris Therapeutics in a report issued on Tuesday, May 10th. SVB Leerink analyst T. Smith now anticipates that the biotechnology company will earn ($0.31) per share for the quarter, up from their prior forecast of ($0.46). SVB Leerink also issued estimates for Aclaris Therapeutics’ Q3 2022 earnings at ($0.33) EPS, Q4 2022 earnings at ($0.34) EPS, FY2022 earnings at ($1.28) EPS, FY2023 earnings at ($1.25) EPS, FY2024 earnings at ($1.29) EPS and FY2025 earnings at ($1.46) EPS.

Aclaris Therapeutics (NASDAQ:ACRSGet Rating) last announced its earnings results on Tuesday, May 10th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.10. Aclaris Therapeutics had a negative net margin of 1,256.80% and a negative return on equity of 39.08%. The firm had revenue of $1.45 million during the quarter, compared to analyst estimates of $1.67 million. The business’s quarterly revenue was down 18.2% compared to the same quarter last year.

Several other equities research analysts have also recently commented on ACRS. William Blair restated an “outperform” rating on shares of Aclaris Therapeutics in a research report on Wednesday. Cantor Fitzgerald restated an “overweight” rating on shares of Aclaris Therapeutics in a report on Friday, February 25th. StockNews.com assumed coverage on Aclaris Therapeutics in a report on Thursday, March 31st. They set a “sell” rating on the stock. Finally, Zacks Investment Research raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Aclaris Therapeutics has an average rating of “Buy” and a consensus target price of $30.50.

Shares of NASDAQ:ACRS opened at $10.18 on Friday. The company has a 50 day moving average of $15.28 and a 200-day moving average of $14.09. The firm has a market cap of $623.83 million, a P/E ratio of -7.43 and a beta of 0.67. Aclaris Therapeutics has a twelve month low of $9.26 and a twelve month high of $24.00.

In other Aclaris Therapeutics news, CEO Neal Walker sold 56,303 shares of the firm’s stock in a transaction dated Friday, March 11th. The shares were sold at an average price of $15.91, for a total value of $895,780.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Frank Ruffo sold 12,823 shares of Aclaris Therapeutics stock in a transaction that occurred on Thursday, March 10th. The stock was sold at an average price of $15.55, for a total transaction of $199,397.65. The disclosure for this sale can be found here. Over the last three months, insiders have sold 171,291 shares of company stock valued at $2,694,941. Corporate insiders own 8.20% of the company’s stock.

Several institutional investors have recently modified their holdings of ACRS. Integral Health Asset Management LLC grew its holdings in shares of Aclaris Therapeutics by 19.0% during the first quarter. Integral Health Asset Management LLC now owns 238,000 shares of the biotechnology company’s stock valued at $4,103,000 after buying an additional 38,000 shares in the last quarter. Rhumbline Advisers grew its stake in Aclaris Therapeutics by 18.1% during the 1st quarter. Rhumbline Advisers now owns 55,194 shares of the biotechnology company’s stock valued at $952,000 after acquiring an additional 8,469 shares in the last quarter. MetLife Investment Management LLC increased its holdings in shares of Aclaris Therapeutics by 58.5% in the 1st quarter. MetLife Investment Management LLC now owns 26,282 shares of the biotechnology company’s stock valued at $453,000 after purchasing an additional 9,700 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Aclaris Therapeutics by 20.0% in the first quarter. JPMorgan Chase & Co. now owns 44,650 shares of the biotechnology company’s stock worth $770,000 after purchasing an additional 7,448 shares in the last quarter. Finally, Swiss National Bank boosted its holdings in shares of Aclaris Therapeutics by 7.4% during the first quarter. Swiss National Bank now owns 108,500 shares of the biotechnology company’s stock worth $1,871,000 after purchasing an additional 7,500 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

About Aclaris Therapeutics (Get Rating)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.

Further Reading

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.